Plan B status
This article was originally published in The Tan Sheet
Executive Summary
Barr Labs expects to receive an "approvable" letter from FDA before a Feb. 20 PDUFA deadline for switching its emergency contraceptive pill Plan B (levonorgestrel .75 mg) from prescription to over-the-counter status. During a Feb. 5 earnings call, execs confirmed Barr's R&D group has met recently with the agency regarding the switch application. The Pomona, N.Y.-based firm also maintains the product will be successful for Barr even if it stays an Rx drug. Barr expects to complete the purchase of Plan B developer Women's Capital Corp. within the next two weeks; the firm signed a letter of intent to purchase WCC in October 2003 (1"The Tan Sheet" Oct. 6, 2003, p. 3)...
You may also be interested in...
Barr Plans Move To OTC Market With Plan B Emergency Contraceptive
Barr Laboratories will continue to pursue an Rx-to-OTC switch for the emergency contraceptive Plan B following its planned acquisition of the product
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.